These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 17419264)

  • 1. Treatment of advanced hepatocellular carcinoma with gemcitabine plus oxaliplatin.
    Li S; Niu Z; Tian H; Zhang B; Wang F; Yi LH; Yu J
    Hepatogastroenterology; 2007; 54(73):218-23. PubMed ID: 17419264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules.
    Taïeb J; Bonyhay L; Golli L; Ducreux M; Boleslawski E; Tigaud JM; de Baere T; Mansourbakht T; Delgado MA; Hannoun L; Poynard T; Boige V
    Cancer; 2003 Dec; 98(12):2664-70. PubMed ID: 14669287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study.
    Asnacios A; Fartoux L; Romano O; Tesmoingt C; Louafi S S; Mansoubakht T; Artru P; Poynard T; Rosmorduc O; Hebbar M; Taieb J
    Cancer; 2008 Jun; 112(12):2733-9. PubMed ID: 18412149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.
    Zhu AX; Blaszkowsky LS; Ryan DP; Clark JW; Muzikansky A; Horgan K; Sheehan S; Hale KE; Enzinger PC; Bhargava P; Stuart K
    J Clin Oncol; 2006 Apr; 24(12):1898-903. PubMed ID: 16622265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma.
    Yang TS; Lin YC; Chen JS; Wang HM; Wang CH
    Cancer; 2000 Aug; 89(4):750-6. PubMed ID: 10951336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of combination of intravenous gemcitabine, oxaliplatin, and 5-FU with daily oral thalidomide (GOFT) in metastatic/locally advanced pancreatic carcinoma patients.
    Shan YS; Lin PW
    Hepatogastroenterology; 2007; 54(79):2141-5. PubMed ID: 18251177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. INST OX-05-024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial.
    Patt YZ; Murad W; Fekrazad MH; Baron AD; Bansal P; Boumber Y; Steinberg K; Lee SJ; Bedrick E; Du R; Lee FC
    Cancer Med; 2017 Sep; 6(9):2042-2051. PubMed ID: 28801995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study.
    Louafi S; Boige V; Ducreux M; Bonyhay L; Mansourbakht T; de Baere T; Asnacios A; Hannoun L; Poynard T; Taïeb J
    Cancer; 2007 Apr; 109(7):1384-90. PubMed ID: 17330837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma.
    Williet N; Dubreuil O; Boussaha T; Trouilloud I; Landi B; Housset M; Botti M; Rougier P; Belghiti J; Taieb J
    World J Gastroenterol; 2011 May; 17(17):2255-8. PubMed ID: 21633538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study.
    Liu Y; Yue H; Xu S; Wang F; Ma N; Li K; Qiao L; Wang J
    Int J Clin Oncol; 2015 Oct; 20(5):952-9. PubMed ID: 25712158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer.
    Ch'ang HJ; Wang CC; Cheng AL; Hsu C; Lu YS; Chang MC; Lin JT; Wang HP; Shiah HS; Liu TW; Chang JY; Whang-Peng J; Chen LT
    J Gastroenterol Hepatol; 2006 May; 21(5):874-9. PubMed ID: 16704539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
    Tsavaris N; Kosmas C; Skopelitis H; Gouveris P; Kopterides P; Loukeris D; Sigala F; Zorbala-Sypsa A; Felekouras E; Papalambros E
    Invest New Drugs; 2005 Aug; 23(4):369-75. PubMed ID: 16012797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib.
    Mir O; Coriat R; Boudou-Rouquette P; Ropert S; Durand JP; Cessot A; Mallet V; Sogni P; Chaussade S; Pol S; Goldwasser F
    Med Oncol; 2012 Dec; 29(4):2793-9. PubMed ID: 22427209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of advanced hepatocellular carcinoma with biweekly high-dose gemcitabine.
    Ulrich-Pur H; Kornek GV; Fiebiger W; Schüll B; Raderer M; Scheithauer W
    Oncology; 2001; 60(4):313-5. PubMed ID: 11408798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
    Poplin E; Feng Y; Berlin J; Rothenberg ML; Hochster H; Mitchell E; Alberts S; O'Dwyer P; Haller D; Catalano P; Cella D; Benson AB
    J Clin Oncol; 2009 Aug; 27(23):3778-85. PubMed ID: 19581537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
    Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
    Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer.
    Bidoli P; Stani SC; Mariani L; De Candis D; Cortinovis D; Aglione S; Zilembo N; Toffolatti L; Formisano B; Bajetta E
    Lung Cancer; 2004 Feb; 43(2):203-8. PubMed ID: 14739041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma.
    Starling N; Hawkes EA; Chau I; Watkins D; Thomas J; Webb J; Brown G; Thomas K; Barbachano Y; Oates J; Cunningham D
    Ann Oncol; 2012 Apr; 23(4):942-7. PubMed ID: 21750117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine and oxaliplatin in patients with metastatic breast cancer resistant to or pretreated with both anthracyclines and taxanes: clinical and pharmacokinetic data.
    Airoldi M; Cattel L; Passera R; Pedani F; Delprino L; Micari C
    Am J Clin Oncol; 2006 Oct; 29(5):490-4. PubMed ID: 17023785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.